1 – 10 of 12
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2024
-
Mark
Health-related quality of life and physical activity in Nordic patients with moderate haemophilia A and B (the MoHem study)
(
- Contribution to journal › Article
- 2023
-
Mark
No difference in quality of life between persons with severe haemophilia A and B
(
- Contribution to journal › Article
-
Mark
Matching-adjusted indirect comparison of bleeding outcomes in severe haemophilia A : Comparing valoctocogene roxaparvovec gene therapy, emicizumab prophylaxis, and FVIII replacement prophylaxis
(
- Contribution to journal › Article
- 2022
-
Mark
Pain, depression and anxiety in people with haemophilia from three Nordic countries : Cross-sectional survey data from the MIND study
(
- Contribution to journal › Article
-
Mark
Immune tolerance induction in the era of emicizumab – still the first choice for patients with haemophilia A and inhibitors?
(
- Contribution to journal › Article
-
Mark
Surgical outcomes in patients with haemophilia A or B receiving extended half-life recombinant factor VIII and IX Fc fusion proteins : Real-world experience in the Nordic countries
(
- Contribution to journal › Article
- 2021
-
Mark
Validation of factor VIII activity for monitoring standard and extended half-life products and correlation to thrombin generation assays
(
- Contribution to journal › Article
-
Mark
Real-world prophylactic usage of recombinant factor VIII Fc in Sweden : A report from the Swedish national registry for bleeding disorders
(
- Contribution to journal › Letter
- 2017
-
Mark
Anti-factor VIII antibodies in brothers with haemophilia A share similar characteristics
(
- Contribution to journal › Article
- 2010
-
Mark
Clinical issues in inhibitors
(
- Contribution to journal › Scientific review